Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells

Mostra altre versioni (1)

Factors that regulate the induction of apoptosis of tumour cells are potential candidates for therapeutic intervention for the majority of cancers. Studying modifiers of apoptotic responses, such as members of the tumour necrosis factor receptor superfamily, may give clues as to how induction of apo...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Cross, N, Waterman, E, Jokonya, N, Fowles, A, Buckle, C, Phillips, J, Holen, I, Hamdy, F, Eaton, C
Natura:	Journal article
Lingua:	English
Pubblicazione:	2008

Documenti analoghi

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
di: Cross, N, et al.
Pubblicazione: (2008)

Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.
di: Cross, N, et al.
Pubblicazione: (2008)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
di: Nyambo, R, et al.
Pubblicazione: (2004)

The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.
di: Cross, N, et al.
Pubblicazione: (2005)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
di: Nyambo, R, et al.
Pubblicazione: (2004)

Analysis of the functional role of ADAMTS enzymes in prostate cancer
di: Molokwu, C, et al.
Pubblicazione: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
di: Waterman, E, et al.
Pubblicazione: (2007)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
di: Holen, I, et al.
Pubblicazione: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
di: Eaton, C, et al.
Pubblicazione: (2004)

Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines
di: Chandrasekharan, S, et al.
Pubblicazione: (2003)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
di: Holen, I, et al.
Pubblicazione: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
di: Eaton, C, et al.
Pubblicazione: (2004)

Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro
di: Papageorgiou, M, et al.
Pubblicazione: (2005)

EZH2 promotes proliferation and invasiveness of prostate cancer cells.
di: Bryant, R, et al.
Pubblicazione: (2007)

Evaluating the role of ADAMTS proteoglycanases and TIMP-3 in prostate cancer progression
di: Adeniji, O, et al.
Pubblicazione: (2007)

TIMP-3 expression is regulated by androgen and TNF in prostate stromal and cancer cells
di: Adeniji, O, et al.
Pubblicazione: (2008)

TIMP-3 expression in prostate stromal and tumour cells is regulated by androgen and TNF
di: Adeniji, O, et al.
Pubblicazione: (2007)

The role of osteoprotegerin in breast and prostate cancer
di: Holen, I, et al.
Pubblicazione: (2002)

BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype.
di: Darby, S, et al.
Pubblicazione: (2008)

OPG is a survival factor for breast- and prostate cancer cells in vitro
di: Holen, I, et al.
Pubblicazione: (2002)

The polycomb group protein EZH2 is required for transcriptional repression of p21 and MMP7 in prostate cancer cells
di: Bryant, R, et al.
Pubblicazione: (2007)

Trailing TRAIL Resistance: Novel Targets for TRAIL sensitization in Cancer cells
di: RACHANA eTRIVEDI, et al.
Pubblicazione: (2015-04-01)

Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
di: Korie A Grayson, et al.
Pubblicazione: (2021-01-01)

Qualitative and quantitative PSA mRNA detection in prostate cancer - A useful tool for the clinician?
di: Phillips, J, et al.
Pubblicazione: (2007)

Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer.
di: Mitchell, A, et al.
Pubblicazione: (2013)

High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde
di: Lee Jae-Won, et al.
Pubblicazione: (2011-04-01)

Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action
di: Cross, N, et al.
Pubblicazione: (2007)

Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis
di: Oliver H. Voss, et al.
Pubblicazione: (2021-03-01)

HIV induces TRAIL sensitivity in hepatocytes.
di: Challagundla K Babu, et al.
Pubblicazione: (2009-01-01)

The emphysematous lung is abnormally sensitive to TRAIL-mediated apoptosis
di: Milot Julie, et al.
Pubblicazione: (2011-08-01)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
di: Rehman, I, et al.
Pubblicazione: (2008)

Differential sensitivity of normal osteoblast-like cells and osteosarcoma cells to TRAIL and an agonist antibody to TRAIL receptor-2
di: Locklin, R, et al.
Pubblicazione: (2005)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
di: Glen, A, et al.
Pubblicazione: (2008)

Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.
di: Masakatsu Oishi, et al.
Pubblicazione: (2013-01-01)

Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases
di: L.A. Braga-Silva, et al.
Pubblicazione: (2009-08-01)

iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
di: Rehman, I, et al.
Pubblicazione: (2012)

Diurnal variation of non-specular meteor trails
di: J. Hinrichs, et al.
Pubblicazione: (2009-05-01)

Global variation of meteor trail plasma turbulence
di: L. P. Dyrud, et al.
Pubblicazione: (2011-12-01)

Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations
di: Rehman, I, et al.
Pubblicazione: (2004)

Trail without Catheter after Transurethral Resection of Prostate: Clamp It or Not?
di: Vikash Talreja, et al.
Pubblicazione: (2016-01-01)